Lilly reports strong weight loss results for new drug

Lilly reports strong weight loss results for new drug: the analysis positions LLY, WST and MCK to benefit and NVO, VKTX and ALT under pressure; confidence medium.

Analyzed 2026-09-30 — point-in-time, never revised. Outcomes are scored against SPY and published either way.

Ranked exposures

▲ LLY Eli Lilly — impact +94 · confidence medium · horizon immediate · 1st order
Superior efficacy expands Lilly’s obesity-treatment demand, enabling pricing power and broader patient penetration beyond Zepbound.
Chain: retatrutide trial delivers superior weight reduction → prescriber preference shifts toward Lilly portfolio → payer coverage supports premium net price → obesity franchise revenue and volumes expand
What would break the call: Regulatory delay or a tolerability signal in the filing dataset blocks approval and removes the revenue ramp.
▼ NVO Novo Nordisk — impact -82 · confidence medium · horizon immediate · 1st order
Lilly’s superior obesity-treatment efficacy shifts prescribers from Novo Nordisk, reducing Wegovy volumes and realized pricing.
Chain: Lilly posts higher percentage weight loss → prescribers switch new starts away from semaglutide → Wegovy volume growth slows → Novo concedes rebates to hold formulary share
What would break the call: Novo cardiovascular or kidney outcomes data wins formulary preference despite lower weight loss.
▼ VKTX Viking Therapeutics — impact -70 · confidence medium · horizon immediate · 2nd order
Lilly’s stronger efficacy raises Viking’s obesity-treatment benchmark, weakening candidate differentiation and partnership value.
Chain: Lilly raises efficacy benchmark for obesity drugs → Viking candidate differentiation narrows on cross trial comparison → partner interest and licensing economics weaken → funding cost for late stage trials rises
What would break the call: Viking oral VK2735 data shows comparable loss with better tolerability, restoring partnership interest.
▼ ALT Altimmune — impact -68 · confidence low · horizon immediate · 2nd order
Altimmune's development program becomes less competitive as Lilly establishes stronger clinical efficacy and safety expectations.
Chain: Lilly sets higher standard for obesity efficacy → Altimmune pemvidutide profile looks less competitive → investor probability of partnership declines → capital raising terms become more dilutive
What would break the call: Pemvidutide MASH data secures a licensing deal on non obesity grounds.
▲ WST West Pharmaceutical Services — impact +53 · confidence medium · horizon quarters · 2nd order
Lilly’s expanding obesity-drug production increases demand for West’s elastomer stoppers and delivery components.
Chain: obesity drug volumes scale with new approval → injectable filling capacity expands at Lilly → orders rise for stoppers and plungers → West high value component revenue grows
What would break the call: Oral obesity pills capture the incremental volume and injectable component orders stay flat.
▼ AMGN Amgen — impact -50 · confidence medium · horizon weeks · 1st order
Lilly’s superior weight-loss efficacy intensifies competition for Amgen, reducing MariTide’s peak sales potential and launch pricing.
Chain: Lilly demonstrates deeper weight loss → MariTide differentiation on dosing interval matters less → expected launch price and share fall → obesity pipeline value in Amgen model shrinks
What would break the call: MariTide phase three shows strong tolerability and durable loss with monthly dosing.
▼ HIMS Hims & Hers Health — impact -48 · confidence low · horizon quarters · 2nd order
Branded treatment availability can reduce demand for compounded weight loss medications sold through telehealth channels.
Chain: branded supply and efficacy improve → compounded semaglutide demand loses appeal → telehealth subscriber mix shifts to lower margin → Hims weight loss revenue growth slows
What would break the call: Hims signs a branded distribution agreement that converts subscribers at similar margins.
▲ MCK McKesson — impact +47 · confidence low · horizon quarters · 2nd order
McKesson earns distribution fees on high priced specialty prescriptions, so rising obesity script volume expands revenue and buying economics.
Chain: obesity script volumes grow across pharmacies → specialty distribution units flow through McKesson → fee for service and buy side economics scale → US pharmaceutical segment revenue rises
What would break the call: Manufacturer direct to patient shipping bypasses wholesalers on the new drug.
▲ TMO Thermo Fisher Scientific — impact +46 · confidence medium · horizon quarters · 2nd order
Lilly’s obesity-drug capacity expansion increases Thermo Fisher’s contract manufacturing and fill-finish revenue.
Chain: Lilly expands peptide and fill finish capacity → outsourced manufacturing and device assembly demand rises → Thermo pharma services backlog grows → bioproduction consumable revenue follows
What would break the call: Lilly keeps the new drug fully in house at Lebanon and Concord sites.
▲ COR Cencora — impact +45 · confidence low · horizon quarters · 2nd order
Cencora distributes branded weight loss drugs at scale, and larger dispensed volumes raise revenue per pharmacy customer.
Chain: dispensed obesity units increase nationally → Cencora distributes branded specialty products → revenue per pharmacy customer rises → US healthcare solutions profit grows
What would break the call: Direct manufacturer channels or a pricing reset cut wholesaler unit economics.
▼ PFE Pfizer — impact -43 · confidence low · horizon weeks · 2nd order
Pfizer's obesity drug ambitions lose strategic appeal when Lilly widens its clinical and commercial advantage.
Chain: Lilly widens obesity efficacy lead → Pfizer acquired metsera assets face tougher benchmark → expected obesity revenue contribution declines → capital allocation case weakens
What would break the call: Pfizer reports competitive amylin combination data with clean tolerability.
▲ DHR Danaher — impact +41 · confidence medium · horizon quarters · 3rd order
Higher obesity-drug output increases Danaher’s recurring bioprocessing equipment and filtration-consumable order flow.
Chain: obesity drug output expands manufacturing capacity → peptide purification and filtration needs grow → Danaher bioprocessing consumable orders rise → recurring revenue and book to bill improve
What would break the call: Peptide synthesis uses non Danaher chemical routes and bioprocessing orders stay soft.
▼ MED Medifast — impact -40 · confidence low · horizon quarters · 2nd order
Medifast sells structured meal replacement programs that keep losing customers to pharmacological weight loss options.
Chain: effective drugs replace diet program demand → Medifast coach recruitment and customer count fall → revenue per active earning coach declines → top line contraction continues
What would break the call: Medifast nutrition support partnership with a telehealth provider stabilizes customer counts.
▲ CAH Cardinal Health — impact +38 · confidence low · horizon quarters · 2nd order
Cardinal Health moves more branded specialty units through its pharmaceutical segment as obesity prescriptions grow across retail channels.
Chain: branded obesity prescriptions grow at retail → Cardinal distributes those units to pharmacies → pharmaceutical segment revenue increases → generic program economics stay intact
What would break the call: Loss of a major pharmacy contract or direct shipping removes the volume benefit.
▼ RMD ResMed — impact -35 · confidence low · horizon quarters · 3rd order
ResMed faces weaker future sleep apnea device demand because sustained weight loss lowers diagnosis and mask replacement rates.
Chain: sustained weight loss reduces obesity prevalence → sleep apnea severity and diagnosis rates fall → new device and mask starts slow → ResMed resupply revenue growth decelerates
What would break the call: ResMed data again shows drug treated patients increase PAP starts and resupply.
▼ HSY Hershey — impact -33 · confidence low · horizon quarters · 3rd order
Hershey sells confectionery volumes that shrink as appetite suppressing therapy spreads through the adult snacking population.
Chain: appetite suppression spreads across adult population → discretionary confectionery occasions decline → Hershey volume growth turns negative → price mix cannot offset lost volume
What would break the call: Scanner data shows confectionery volumes holding while cocoa costs drive the narrative.
▼ KHC Kraft Heinz — impact -30 · confidence low · horizon quarters · 3rd order
Kraft Heinz relies on calorie dense packaged staples, and broader drug adoption trims household purchase volumes.
Chain: treated households cut calorie intake → packaged staple purchase volumes shrink → Kraft Heinz elasticity worsens → organic volume decline deepens
What would break the call: Portfolio reshaping toward protein and lower calorie brands restores volume growth.
▲ CVS CVS Health — impact +30 · confidence low · horizon quarters · 2nd order
CVS fills more branded obesity scripts in retail pharmacy while Caremark collects rebate and administration fees on the spend.
Chain: obesity script count rises nationally → CVS retail pharmacy dispenses more branded units → Caremark collects rebate and administration fees → front store and pharmacy revenue grows
What would break the call: Aetna medical cost inflation from covering the drug outweighs pharmacy and Caremark gains.
▲ IQV IQVIA — impact +30 · confidence low · horizon quarters · 2nd order
IQVIA runs the large cardiometabolic trials and real world evidence work that expanding obesity pipelines now require.
Chain: obesity efficacy bar rises industry wide → sponsors fund larger outcomes and comparator trials → IQVIA clinical research bookings increase → real world evidence demand expands
What would break the call: Biotech funding contraction cuts overall trial starts despite obesity activity.
▼ GIS General Mills — impact -28 · confidence low · horizon quarters · 3rd order
General Mills sees cereal and snack demand soften as treated consumers cut portion sizes and basket counts.
Chain: drug treated consumers reduce portion sizes → cereal and snack purchase frequency declines → General Mills volume growth weakens → promotional spend rises to defend share
What would break the call: Pet and protein segment growth offsets cereal softness in reported organic sales.
▲ BDX Becton Dickinson — impact +28 · confidence low · horizon quarters · 2nd order
BD supplies prefillable syringes and needles, so expanding injectable obesity volumes raise pharmaceutical systems unit demand.
Chain: injectable obesity prescriptions scale up → autoinjector and syringe component demand rises → BD pharmaceutical systems orders increase → segment revenue and mix improve
What would break the call: Lilly standardizes on a competing device platform or oral dosing.
▲ CRL Charles River Laboratories — impact +26 · confidence low · horizon quarters
Charles River sells preclinical services and research models as sponsors accelerate obesity programs chasing stronger efficacy data.
▼ DVA DaVita — impact -25 · confidence low · horizon quarters
DaVita adds fewer new dialysis patients over time as metabolic and renal disease progression slows among diabetics.
▼ PODD Insulet — impact -24 · confidence low · horizon quarters
Insulet faces slower type two pump adoption when glucose control improves and insulin dependence falls.

Sources

What happened

Horizon	Verdict	Top pick	Excess vs SPY
1 trading days	Wrong	LLY	-2.1% vs SPY
5 trading days	Wrong	LLY	-4.2% vs SPY

Related scenarios

Stocks in this scenario

LLY · NVO · VKTX · ALT · WST · AMGN · HIMS · MCK · TMO · COR · PFE · DHR · MED · CAH · RMD · HSY · KHC · CVS · IQV · GIS · BDX · CRL · DVA · PODD · RYTM · DXCM · UNH · NVS

News events · All scenarios · Pricing · Track record · Methodology · Map your own scenario